Endostar continuous intravenous infusion — Competitive Intelligence Brief

Endostar continuous intravenous infusion (Endostar continuous intravenous infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiogenesis inhibitor. Area: Oncology.

phase 3 Angiogenesis inhibitor VEGF signaling pathway; endothelial cells Oncology Small molecule

Target snapshot

Endostar continuous intravenous infusion (Endostar continuous intravenous infusion) — Jiangsu Simcere Pharmaceutical Co., Ltd.. Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Endostar continuous intravenous infusion TARGET	Endostar continuous intravenous infusion	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	Angiogenesis inhibitor	VEGF signaling pathway; endothelial cells
Rh-endostatin	Rh-endostatin	Guangzhou Institute of Respiratory Disease	phase 3	Angiogenesis inhibitor	VEGF signaling pathway; endothelial cells
Endostar routine intravenous infusion	Endostar routine intravenous infusion	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	Angiogenesis inhibitor	VEGF signaling pathway; endothelial cells
recombinant human endostatin	recombinant human endostatin	Peking University Cancer Hospital & Institute	marketed	Angiogenesis inhibitor	Endothelial cells (multiple pathways including integrin and VEGF-related mechanisms)
endostar+chemoradiotherapy	endostar+chemoradiotherapy	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Angiogenesis inhibitor	Endothelial cells; inhibits multiple angiogenic pathways
ENDOSTAR，cisplatin	ENDOSTAR，cisplatin	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	Angiogenesis inhibitor	Endothelial cells; inhibits VEGF-mediated angiogenesis
bevacizumab + triamcinolone acetonide	bevacizumab + triamcinolone acetonide	Shahid Beheshti University of Medical Sciences	phase 3	Angiogenesis inhibitor, Corticosteroid	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiogenesis inhibitor class)

1. Jiangsu Simcere Pharmaceutical Co., Ltd. · 3 drugs in this class
2. Eli Lilly and Company · 1 drug in this class
3. Guangzhou Institute of Respiratory Disease · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. Liaoning Cancer Hospital & Institute · 1 drug in this class
6. PPD Development, LP · 1 drug in this class
7. Peking University Cancer Hospital & Institute · 1 drug in this class
8. Sanofi · 1 drug in this class
9. ARCAGY/ GINECO GROUP · 1 drug in this class
10. Second Affiliated Hospital of Xi'an Jiaotong University · 1 drug in this class